-INCLUSION CRITERIA:

          1. Metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3 as
             assessed by one of the following methods: RT-PCR on tumor tissue defined as 30,000
             copies of MAGE-A3 per 10^6 GAPDH copies, or by immunohistochemistry of resected tissue
             defined as 10% or greater of tumor cells being 2-3+ for MAGE-A3, or serum antibody
             reactive with MAGE-A3. Metastatic cancer diagnosis will be confirmed by the Laboratory
             of Pathology at the NCI.

          2. Patients must have previously received prior first line standard therapy (or effective
             salvage chemotherapy regimens) for their disease, if known to be effective for that
             disease, and have been either non-responders (progressive disease) or have recurred.

          3. Patients must be HLA-DP4 positive.

          4. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible. Patients with surgically resected brain metastases are eligible.

          5. Greater than or equal to 18 years of age and less than or equal to age 70.

          6. Ability of subject to understand and the willingness to sign the Informed Consent
             Document.

          7. Willing to sign a durable power of attorney

          8. Clinical performance status of ECOG 0 or 1

          9. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for up to four months after treatment.

         10. Serology:

               -  Seronegative for HIV antibody. (The experimental treatment being evaluated in
                  this protocol depends on an intact immune system. Patients who are HIV
                  seropositive can have decreased immune-competence and thus be less responsive to
                  the experimental treatment and more susceptible to its toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then patient must be tested for the
                  presence of antigen by RT-PCR and be HCV RNA negative.

         11. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         12. Hematology

               -  Absolute neutrophil count greater than 1000/mm^3 without the support of
                  filgrastim

               -  WBC greater than or equal to 3000/mm^3

               -  Platelet count greater than or equal to 100,000/mm^3

               -  Hemoglobin > 8.0 g/dl

         13. Chemistry:

               -  Serum ALT/AST less than or equal to 2.5 times the upper limit of normal

               -  Serum creatinine less than or equal to 1.6 mg/dl

               -  Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert
                  s Syndrome who must have a total bilirubin less than 3.0 mg/dl.

         14. More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients' toxicities must have
             recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).
             Patients must have

             progressing disease after prior treatment. Note: Patients who have previously received
             ipilimumab and have documented GI toxicity must have a normal colonoscopy with normal
             colonic biopsies.

         15. Subjects must be co-enrolled in protocol 03-C-0277.

        EXCLUSION CRITERIA:

          1. Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          2. Active systemic infections, (e.g.: requiring anti-infective treatment), coagulation
             disorders or any other active major medical illnesses

          3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          4. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          5. Concurrent systemic steroid therapy.

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          7. History of any cardiac events including coronary revascularization or ischemic
             symptoms.

          8. Documented LVEF of less than or equal to 45% testing is required in patients who are

               -  greater than or equal to 65 years old

               -  Clinically significant atrial and or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block or have a history of ischemic heart disease, or chest pain.

          9. Documented FEV1 less than or equal to 60% predicted tested in patients with:

               -  A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2
                  years).

               -  Symptoms of respiratory dysfunction

         10. Patients who are receiving any other investigational agents.